Iveda director reports 25K option repricing

Iveda Solutions director Franco Alejandro reported an option repricing and related award.

Rhea-AI Filing Summary

Iveda Solutions director Franco Alejandro reported an option repricing and related award. On February 23, 2026, the board approved a repricing of his options to an exercise price of $0.29 per share, with all other terms unchanged. This involved an acquisition of 25,000 options and a corresponding disposition of 25,000 options to the issuer, both recorded at a transaction price of $0.00 per option. Following these transactions, Alejandro directly held 53,130 options to acquire Iveda Solutions stock. The company notes these transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

Insights

Equity compensation analyst

Director’s option repricing and related award look administrative and neutral.

The filing shows Franco Alejandro, a director of Iveda Solutions, had his stock options repriced by the board to an exercise price of $0.29 per share. This was implemented through a grant of 25,000 options and a matching disposition of 25,000 options back to the issuer.

The net result leaves Alejandro with 53,130 options outstanding, so the reported changes primarily alter the strike price rather than the overall scale of his equity exposure. The company states the transactions were exempt under Rule 16b-6(d) and Rule 16b-3, indicating they were structured within standard insider and compensation rules.

Because the grant and disposition offset one another in share count terms and there is no cash consideration disclosed, this development appears to be a routine compensation adjustment rather than a directional bet. It would generally be viewed as neutral for existing shareholders based solely on the disclosed figures.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Franco Alejandro

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	25,000	$0.00	$0.00
Disposition	Options (Right to Buy)	25,000	$0.00	$0.00

Holdings After Transaction: Options (Right to Buy) — 106,260 contracts (Direct)

Footnotes (1)

1. F1. On February 23, 2026, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $0.29 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Iveda Solutions (IVDA) director Franco Alejandro’s latest Form 4 report?

The Form 4 reports a board-approved repricing of Franco Alejandro’s stock options to an exercise price of $0.29 per share, involving a grant of 25,000 options and a corresponding disposition of 25,000 options back to Iveda Solutions as the issuer.

How many Iveda Solutions options does Franco Alejandro hold after the reported transactions?

After the reported transactions, Franco Alejandro directly holds 53,130 options to buy Iveda Solutions stock. This balance reflects the combined effect of a 25,000-option grant and a 25,000-option disposition related to the repricing approved by the company’s board.

What was the exercise price set in Iveda Solutions’ option repricing for Franco Alejandro?

The option repricing set Franco Alejandro’s stock option exercise price at $0.29 per share. According to the disclosure, Iveda Solutions’ board approved this repricing on February 23, 2026, and all other terms of the options remained unchanged after the adjustment.

Were cash proceeds involved in Franco Alejandro’s Iveda Solutions option transactions?

The disclosed transactions list a $0.00 per option transaction price, indicating no cash consideration in the recorded grant and disposition. The changes reflect a repricing to an exercise price of $0.29 per share rather than a purchase or sale for cash in the market.

What regulatory exemptions apply to Franco Alejandro’s Iveda Solutions option repricing?

The company states the option repricing and related transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act. These exemptions typically cover certain issuer-related derivative transactions and board-approved compensation arrangements for insiders such as directors.

Did the Iveda Solutions Form 4 indicate insider buying or selling by Franco Alejandro?

The Form 4 shows an acquisition of 25,000 options and a matching disposition to the issuer of 25,000 options, both at a transaction price of $0.00. Combined with the repricing to $0.29, this appears as a compensation adjustment rather than open-market buying or selling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Franco Alejandro

(Last) (First) (Middle)

1744 S. VAL VISTA DRIVE,

STE. 213

(Street)

MESA AZ 85204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Iveda Solutions, Inc. [ IVDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.82	12/29/2025		D		25,000		12/29/2025	12/29/2035	Common Stock	25,000	$0.00	53,130	D
Options (Right to Buy)	$0.29(1)	02/23/2026		A		25,000		12/29/2025	12/29/2035	Common Stock	25,000	$0.00	53,130	D

Explanation of Responses:

1. On February 23, 2026, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $0.29 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

	/s/ Alejandro L. Franco	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.